Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Innate Pharma (IPHA) Operating Margin (2021 - 2024)

Innate Pharma posted quarterly Operating Margin of 317.29% for Q2 2024, down 31617.0% year-on-year from N/an in Q3 2023, and down 28076.78% on a QoQ basis from 1.13% in Q2 2023.

Innate Pharma (IPHA) has 3 years of Operating Margin data on file, last reported at 317.29% in Q2 2024.

  • For the quarter ending Q2 2024, Operating Margin fell 31617.0% year-over-year to 317.29%; the trailing twelve-month figure through Jun 2024 stood at 46.86% (down 1735.0% YoY), and the FY2025 full-year result was 1937.85%, down 168153.0% from the prior year.
  • Operating Margin for Q2 2024 stood at 317.29%, down from 1.13% in the prior quarter.
  • Across five years, Operating Margin topped out at 1.13% in Q2 2023 and bottomed at 317.29% in Q2 2024.
  • The 3-year median for Operating Margin is 193.6% (2021), against an average of 170.67%.
  • Peak annual rise in Operating Margin reached 31617 bps in 2024, while the deepest fall reached 31617 bps in 2024.
  • A 3-year view of Operating Margin shows it stood at 193.6% in 2021, then jumped by 99 bps to 1.13% in 2023, then plunged by 28077 bps to 317.29% in 2024.
  • The last three Operating Margin figures came in at 317.29% (Q2 2024), 1.13% (Q2 2023), and 193.6% (Q4 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 38.10%
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 17.83%
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 23.02%
10 Innate Pharma 199.64 Mn 199.64 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2024 -317.29%
Jun 30, 2023 -1.13%
Dec 31, 2021 -193.60%